View of Enlicitide (Lipfendra): the first oral PCSK9 inhibitor - from macrocyclic peptide innovation to clinical translation

Return to Article Details Enlicitide (Lipfendra): the first oral PCSK9 inhibitor - from macrocyclic peptide innovation to clinical translation Download Download PDF